Abstract
Neurofibrillary tangles (NFTs), composed of truncated and hyperphosphorylated tau, are a common feature of numerous aging-related neurodegenerative diseases, including Alzheimer's disease (AD). However, the molecular mechanisms mediating tau truncation and aggregation during aging remain elusive. Here we show that asparagine endopeptidase (AEP), a lysosomal cysteine proteinase, is activated during aging and proteolytically degrades tau, abolishes its microtubule assembly function, induces tau aggregation and triggers neurodegeneration. AEP is upregulated and active during aging and is activated in human AD brain and tau P301S–transgenic mice with synaptic pathology and behavioral impairments, leading to tau truncation in NFTs. Tau P301S–transgenic mice with deletion of the gene encoding AEP show substantially reduced tau hyperphosphorylation, less synapse loss and rescue of impaired hippocampal synaptic function and cognitive deficits. Mice infected with adeno-associated virus encoding an uncleavable tau mutant showed attenuated pathological and behavioral defects compared to mice injected with adeno-associated virus encoding tau P301S. Together, these observations indicate that AEP acts as a crucial mediator of tau-related clinical and neuropathological changes. Inhibition of AEP may be therapeutically useful for treating tau-mediated neurodegenerative diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ballatore, C., Lee, V.M. & Trojanowski, J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8, 663–672 (2007).
Binder, L.I., Frankfurter, A. & Rebhun, L.I. The distribution of tau in the mammalian central nervous system. J. Cell. Biol. 101, 1371–1378 (1985).
Harada, A. et al. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369, 488–491 (1994).
Esmaeli-Azad, B., McCarty, J.H. & Feinstein, S.C. Sense and antisense transfection analysis of tau function: tau influences net microtubule assembly, neurite outgrowth and neuritic stability. J. Cell Sci. 107, 869–879 (1994).
Caceres, A. & Kosik, K.S. Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature 343, 461–463 (1990).
Dixit, R., Ross, J.L., Goldman, Y.E. & Holzbaur, E.L. Differential regulation of dynein and kinesin motor proteins by tau. Science 319, 1086–1089 (2008).
Lindwall, G. & Cole, R.D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259, 5301–5305 (1984).
Iqbal, K., Zaidi, T., Bancher, C. & Grundke-Iqbal, I. Alzheimer paired helical filaments. Restoration of the biological activity by dephosphorylation. FEBS Lett. 349, 104–108 (1994).
Köpke, E. et al. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 268, 24374–24384 (1993).
Alonso, A.C., Grundke-Iqbal, I. & Iqbal, K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 2, 783–787 (1996).
Alonso, A.C., Zaidi, T., Grundke-Iqbal, I. & Iqbal, K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl. Acad. Sci. USA 91, 5562–5566 (1994).
Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I. & Iqbal, K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. USA 98, 6923–6928 (2001).
Gamblin, T.C. et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 100, 10032–10037 (2003).
Rissman, R.A. et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 114, 121–130 (2004).
Basurto-Islas, G. et al. Accumulation of aspartic acid421– and glutamic acid391–cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J. Neuropathol. Exp. Neurol. 67, 470–483 (2008).
Saito, K., Elce, J.S., Hamos, J.E. & Nixon, R.A. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. USA 90, 2628–2632 (1993).
Park, S.Y. & Ferreira, A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J. Neurosci. 25, 5365–5375 (2005).
Arai, T., Guo, J.P. & McGeer, P.L. Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. J. Biol. Chem. 280, 5145–5153 (2005).
Yang, A.J., Chandswangbhuvana, D., Margol, L. & Glabe, C.G. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Aβ1–42 pathogenesis. J. Neurosci. Res. 52, 691–698 (1998).
Kenessey, A., Nacharaju, P., Ko, L.W. & Yen, S.H. Degradation of tau by lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary degeneration. J. Neurochem. 69, 2026–2038 (1997).
Johnson, G.V. et al. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J. Neurochem. 68, 430–433 (1997).
Portelius, E. et al. Characterization of tau in cerebrospinal fluid using mass spectrometry. J. Proteome Res. 7, 2114–2120 (2008).
Chen, J.M., Dando, P.M., Stevens, R.A., Fortunato, M. & Barrett, A.J. Cloning and expression of mouse legumain, a lysosomal endopeptidase. Biochem. J. 335, 111–117 (1998).
Chen, J.M., Rawlings, N.D., Stevens, R.A. & Barrett, A.J. Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine endopeptidases. FEBS Lett. 441, 361–365 (1998).
Li, D.N., Matthews, S.P., Antoniou, A.N., Mazzeo, D. & Watts, C. Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo. J. Biol. Chem. 278, 38980–38990 (2003).
Liu, Z. et al. Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase. Mol. Cell 29, 665–678 (2008).
Herskowitz, J.H. et al. Asparaginyl endopeptidase cleaves TDP-43 in brain. Proteomics 12, 2455–2463 (2012).
Wang, Y., Garg, S., Mandelkow, E.M. & Mandelkow, E. Proteolytic processing of tau. Biochem. Soc. Trans. 38, 955–961 (2010).
Yates, C.M., Butterworth, J., Tennant, M.C. & Gordon, A. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J. Neurochem. 55, 1624–1630 (1990).
Pirchl, M. & Humpel, C. Neuropsychiatr. [Does acidosis in brain play a role in Alzheimer's disease?] 23, 187–192 (2009).
Basurto-Islas, G., Grundke-Iqbal, I., Tung, Y.C., Liu, F. & Iqbal, K. Activation of asparaginyl endopeptidase leads to tau hyperphosphorylation in Alzheimer disease. J. Biol. Chem. 288, 17495–17507 (2013).
Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337–351 (2007).
Guillozet-Bongaarts, A.L. et al. Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J. Neurochem. 97, 1005–1014 (2006).
Zilka, N. et al. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett. 580, 3582–3588 (2006).
Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T. & Hyman, B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631–639 (1992).
Arriagada, P.V., Marzloff, K. & Hyman, B.T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 42, 1681–1688 (1992).
Braak, H. & Braak, E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 16, 271–278 discussion 278–284 (1995).
Shirahama-Noda, K. et al. Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase–deficient mice. J. Biol. Chem. 278, 33194–33199 (2003).
Kaech, S. & Banker, G. Culturing hippocampal neurons. Nat. Protoc. 1, 2406–2415 (2006).
Elias, J.E. & Gygi, S.P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 4, 207–214 (2007).
Xu, P., Duong, D.M. & Peng, J. Systematical optimization of reverse-phase chromatography for shotgun proteomics. J. Proteome Res. 8, 3944–3950 (2009).
Herskowitz, J.H. et al. Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degeneration. J. Proteome Res. 9, 6368–6379 (2010).
Barghorn, S., Biernat, J. & Mandelkow, E. Purification of recombinant tau protein and preparation of Alzheimer-paired helical filaments in vitro. Methods Mol. Biol. 299, 35–51 (2005).
Hong, Y. et al. SRPK2 phosphorylates tau and mediates the cognitive defects in Alzheimer's disease. J. Neurosci. 32, 17262–17272 (2012).
Jaworski, T. et al. AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS ONE 4, e7280 (2009).
Acknowledgements
This work was supported by RO1grants (NS045627 and NS060680) from the US National Institutes of Health to K.Y., the US National Institutes of Health/National Institute on Aging Alzheimer's Disease Research Centers (P50AG025688) grant to A.I.L., a grant from the National Natural Science Foundation of China (no. 81100958) to Z.Z., a grant from the National Natural Science Foundation of China (no. 91132305) to J.Z.W., a National Key Basic Research Program of China grant (2010CB945202) to Y.E.S. and a National Science Foundation of China grant (81330030) to L.C. and Y.E.S. We thank D. Weinshenker (Emory University) for tau P301S–transgenic mice, M. Asano (Kanazawa University) for Lgmn knockout mice, S. Kuegler (Max Planck Institute of Psychiatry) for pAAV vectors carrying tau GFP and C. Hales (Emory University) for technical support.
Author information
Authors and Affiliations
Contributions
K.Y. conceived the project, designed the experiments and wrote the manuscript. Z.Z. designed and performed most of the experiments. M.S. and S.P.Y. performed the electrophysiological experiments. X.L. prepared primary neurons and assisted with animal experiments. S.S.K. performed the stereotaxic injection of virus. D.M.D. and N.T.S. performed the mass spectrometry analysis. I.-S.K. assisted with the molecular biology experiments. L.C., W.T.H., Z.L., J.Z.-W., Y.E.S. and A.I.L. designed the experiments, assisted with data analysis and interpretation and critically read the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–10 (PDF 1436 kb)
Rights and permissions
About this article
Cite this article
Zhang, Z., Song, M., Liu, X. et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat Med 20, 1254–1262 (2014). https://doi.org/10.1038/nm.3700
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3700
This article is cited by
-
Inhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer’s disease in mice
Neuropsychopharmacology (2024)
-
Quantitative profiling of posttranslational modifications of pathological tau via sarkosyl fractionation and mass spectrometry
Nature Protocols (2024)
-
A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau
Translational Neurodegeneration (2023)
-
Patchouli alcohol attenuates the cognitive deficits in a transgenic mouse model of Alzheimer’s disease via modulating neuropathology and gut microbiota through suppressing C/EBPβ/AEP pathway
Journal of Neuroinflammation (2023)
-
Aberrant palmitoylation caused by a ZDHHC21 mutation contributes to pathophysiology of Alzheimer’s disease
BMC Medicine (2023)